The stock soared 2.31 per cent to Rs 738 on BSE. On NSE too, shares of the company climbed 2.31 per cent to Rs 737.95.
"The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Naproxen Sodium tablets USP, 220 mg," Aurobindo Pharma had said in a BSE filing on Saturday.
"The product is expected to be launched in Q1 of 2016-17," it had said.
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)
Get Breaking news, live coverage, and Latest News from India and around the world on NDTV.com. Catch all the Live TV action on NDTV 24x7 and NDTV India. Like us on Facebook or follow us on Twitter and Instagram for latest news and live news updates.